English
简体中文
Total: £ 56.28
Published Date: 2025-07-15 | Pages: 101 | Tables: 109 | Medical Care
The global market for First in Human (FIH) Studies was valued at US$ 65.3 million in the year 2024 and is projected to reach a revised size of US$ 157 million by 2031, growing at a CAGR of 13.5% during the forecast period.
First in Human (FIH) Studies are the earliest phase of clinical research in which a new drug, biologic, or medical intervention is tested in humans for the first time. These studies are designed primarily to assess safety, tolerability, pharmacokinetics, and initial pharmacodynamic effects in a small group of participants, typically healthy volunteers or, in certain cases, patients. FIH studies are conducted after preclinical testing has demonstrated a reasonable level of safety and potential therapeutic benefit. They play a critical role in determining how the human body responds to a new treatment and guide decisions for further clinical development.
North American market for First in Human (FIH) Studies is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for First in Human (FIH) Studies is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for First in Human (FIH) Studies in Pharmaceutical is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of First in Human (FIH) Studies include Precision for Medicine, Altasciences, hVIVO, QPS Holdings, Worldwide Clinical Trials, Veeda Lifesciences, CMAX, Hammersmith Medicines Research, Allucent, Aixial Group, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for First in Human (FIH) Studies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding First in Human (FIH) Studies.
The First in Human (FIH) Studies market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global First in Human (FIH) Studies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the First in Human (FIH) Studies companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Precision for Medicine
Altasciences
hVIVO
QPS Holdings
Worldwide Clinical Trials
Veeda Lifesciences
CMAX
Hammersmith Medicines Research
Allucent
Aixial Group
Icon Group
BioPharma Services
Simbec-Orion
The Micron Group
BDD
TRACER
Sofpromed
Datapharm Australia
3S Pharma
bioaccess
Pharmaron
WuXi Clinical (WuXi AppTec)
Segment by Type
Healthy Volunteer Studies
Patient Population Studies
Segment by Application
Pharmaceutical
Vaccine
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of First in Human (FIH) Studies company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global First in Human (FIH) Studies Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Healthy Volunteer Studies
1.2.3 Patient Population Studies
1.3 Market by Application
1.3.1 Global First in Human (FIH) Studies Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical
1.3.3 Vaccine
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global First in Human (FIH) Studies Market Perspective (2020-2031)
2.2 Global First in Human (FIH) Studies Growth Trends by Region
2.2.1 Global First in Human (FIH) Studies Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 First in Human (FIH) Studies Historic Market Size by Region (2020-2025)
2.2.3 First in Human (FIH) Studies Forecasted Market Size by Region (2026-2031)
2.3 First in Human (FIH) Studies Market Dynamics
2.3.1 First in Human (FIH) Studies Industry Trends
2.3.2 First in Human (FIH) Studies Market Drivers
2.3.3 First in Human (FIH) Studies Market Challenges
2.3.4 First in Human (FIH) Studies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top First in Human (FIH) Studies Players by Revenue
3.1.1 Global Top First in Human (FIH) Studies Players by Revenue (2020-2025)
3.1.2 Global First in Human (FIH) Studies Revenue Market Share by Players (2020-2025)
3.2 Global Top First in Human (FIH) Studies Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by First in Human (FIH) Studies Revenue
3.4 Global First in Human (FIH) Studies Market Concentration Ratio
3.4.1 Global First in Human (FIH) Studies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by First in Human (FIH) Studies Revenue in 2024
3.5 Global Key Players of First in Human (FIH) Studies Head office and Area Served
3.6 Global Key Players of First in Human (FIH) Studies, Product and Application
3.7 Global Key Players of First in Human (FIH) Studies, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 First in Human (FIH) Studies Breakdown Data by Type
4.1 Global First in Human (FIH) Studies Historic Market Size by Type (2020-2025)
4.2 Global First in Human (FIH) Studies Forecasted Market Size by Type (2026-2031)
5 First in Human (FIH) Studies Breakdown Data by Application
5.1 Global First in Human (FIH) Studies Historic Market Size by Application (2020-2025)
5.2 Global First in Human (FIH) Studies Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America First in Human (FIH) Studies Market Size (2020-2031)
6.2 North America First in Human (FIH) Studies Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America First in Human (FIH) Studies Market Size by Country (2020-2025)
6.4 North America First in Human (FIH) Studies Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe First in Human (FIH) Studies Market Size (2020-2031)
7.2 Europe First in Human (FIH) Studies Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe First in Human (FIH) Studies Market Size by Country (2020-2025)
7.4 Europe First in Human (FIH) Studies Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific First in Human (FIH) Studies Market Size (2020-2031)
8.2 Asia-Pacific First in Human (FIH) Studies Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific First in Human (FIH) Studies Market Size by Region (2020-2025)
8.4 Asia-Pacific First in Human (FIH) Studies Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America First in Human (FIH) Studies Market Size (2020-2031)
9.2 Latin America First in Human (FIH) Studies Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America First in Human (FIH) Studies Market Size by Country (2020-2025)
9.4 Latin America First in Human (FIH) Studies Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa First in Human (FIH) Studies Market Size (2020-2031)
10.2 Middle East & Africa First in Human (FIH) Studies Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa First in Human (FIH) Studies Market Size by Country (2020-2025)
10.4 Middle East & Africa First in Human (FIH) Studies Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Precision for Medicine
11.1.1 Precision for Medicine Company Details
11.1.2 Precision for Medicine Business Overview
11.1.3 Precision for Medicine First in Human (FIH) Studies Introduction
11.1.4 Precision for Medicine Revenue in First in Human (FIH) Studies Business (2020-2025)
11.1.5 Precision for Medicine Recent Development
11.2 Altasciences
11.2.1 Altasciences Company Details
11.2.2 Altasciences Business Overview
11.2.3 Altasciences First in Human (FIH) Studies Introduction
11.2.4 Altasciences Revenue in First in Human (FIH) Studies Business (2020-2025)
11.2.5 Altasciences Recent Development
11.3 hVIVO
11.3.1 hVIVO Company Details
11.3.2 hVIVO Business Overview
11.3.3 hVIVO First in Human (FIH) Studies Introduction
11.3.4 hVIVO Revenue in First in Human (FIH) Studies Business (2020-2025)
11.3.5 hVIVO Recent Development
11.4 QPS Holdings
11.4.1 QPS Holdings Company Details
11.4.2 QPS Holdings Business Overview
11.4.3 QPS Holdings First in Human (FIH) Studies Introduction
11.4.4 QPS Holdings Revenue in First in Human (FIH) Studies Business (2020-2025)
11.4.5 QPS Holdings Recent Development
11.5 Worldwide Clinical Trials
11.5.1 Worldwide Clinical Trials Company Details
11.5.2 Worldwide Clinical Trials Business Overview
11.5.3 Worldwide Clinical Trials First in Human (FIH) Studies Introduction
11.5.4 Worldwide Clinical Trials Revenue in First in Human (FIH) Studies Business (2020-2025)
11.5.5 Worldwide Clinical Trials Recent Development
11.6 Veeda Lifesciences
11.6.1 Veeda Lifesciences Company Details
11.6.2 Veeda Lifesciences Business Overview
11.6.3 Veeda Lifesciences First in Human (FIH) Studies Introduction
11.6.4 Veeda Lifesciences Revenue in First in Human (FIH) Studies Business (2020-2025)
11.6.5 Veeda Lifesciences Recent Development
11.7 CMAX
11.7.1 CMAX Company Details
11.7.2 CMAX Business Overview
11.7.3 CMAX First in Human (FIH) Studies Introduction
11.7.4 CMAX Revenue in First in Human (FIH) Studies Business (2020-2025)
11.7.5 CMAX Recent Development
11.8 Hammersmith Medicines Research
11.8.1 Hammersmith Medicines Research Company Details
11.8.2 Hammersmith Medicines Research Business Overview
11.8.3 Hammersmith Medicines Research First in Human (FIH) Studies Introduction
11.8.4 Hammersmith Medicines Research Revenue in First in Human (FIH) Studies Business (2020-2025)
11.8.5 Hammersmith Medicines Research Recent Development
11.9 Allucent
11.9.1 Allucent Company Details
11.9.2 Allucent Business Overview
11.9.3 Allucent First in Human (FIH) Studies Introduction
11.9.4 Allucent Revenue in First in Human (FIH) Studies Business (2020-2025)
11.9.5 Allucent Recent Development
11.10 Aixial Group
11.10.1 Aixial Group Company Details
11.10.2 Aixial Group Business Overview
11.10.3 Aixial Group First in Human (FIH) Studies Introduction
11.10.4 Aixial Group Revenue in First in Human (FIH) Studies Business (2020-2025)
11.10.5 Aixial Group Recent Development
11.11 Icon Group
11.11.1 Icon Group Company Details
11.11.2 Icon Group Business Overview
11.11.3 Icon Group First in Human (FIH) Studies Introduction
11.11.4 Icon Group Revenue in First in Human (FIH) Studies Business (2020-2025)
11.11.5 Icon Group Recent Development
11.12 BioPharma Services
11.12.1 BioPharma Services Company Details
11.12.2 BioPharma Services Business Overview
11.12.3 BioPharma Services First in Human (FIH) Studies Introduction
11.12.4 BioPharma Services Revenue in First in Human (FIH) Studies Business (2020-2025)
11.12.5 BioPharma Services Recent Development
11.13 Simbec-Orion
11.13.1 Simbec-Orion Company Details
11.13.2 Simbec-Orion Business Overview
11.13.3 Simbec-Orion First in Human (FIH) Studies Introduction
11.13.4 Simbec-Orion Revenue in First in Human (FIH) Studies Business (2020-2025)
11.13.5 Simbec-Orion Recent Development
11.14 The Micron Group
11.14.1 The Micron Group Company Details
11.14.2 The Micron Group Business Overview
11.14.3 The Micron Group First in Human (FIH) Studies Introduction
11.14.4 The Micron Group Revenue in First in Human (FIH) Studies Business (2020-2025)
11.14.5 The Micron Group Recent Development
11.15 BDD
11.15.1 BDD Company Details
11.15.2 BDD Business Overview
11.15.3 BDD First in Human (FIH) Studies Introduction
11.15.4 BDD Revenue in First in Human (FIH) Studies Business (2020-2025)
11.15.5 BDD Recent Development
11.16 TRACER
11.16.1 TRACER Company Details
11.16.2 TRACER Business Overview
11.16.3 TRACER First in Human (FIH) Studies Introduction
11.16.4 TRACER Revenue in First in Human (FIH) Studies Business (2020-2025)
11.16.5 TRACER Recent Development
11.17 Sofpromed
11.17.1 Sofpromed Company Details
11.17.2 Sofpromed Business Overview
11.17.3 Sofpromed First in Human (FIH) Studies Introduction
11.17.4 Sofpromed Revenue in First in Human (FIH) Studies Business (2020-2025)
11.17.5 Sofpromed Recent Development
11.18 Datapharm Australia
11.18.1 Datapharm Australia Company Details
11.18.2 Datapharm Australia Business Overview
11.18.3 Datapharm Australia First in Human (FIH) Studies Introduction
11.18.4 Datapharm Australia Revenue in First in Human (FIH) Studies Business (2020-2025)
11.18.5 Datapharm Australia Recent Development
11.19 3S Pharma
11.19.1 3S Pharma Company Details
11.19.2 3S Pharma Business Overview
11.19.3 3S Pharma First in Human (FIH) Studies Introduction
11.19.4 3S Pharma Revenue in First in Human (FIH) Studies Business (2020-2025)
11.19.5 3S Pharma Recent Development
11.20 bioaccess
11.20.1 bioaccess Company Details
11.20.2 bioaccess Business Overview
11.20.3 bioaccess First in Human (FIH) Studies Introduction
11.20.4 bioaccess Revenue in First in Human (FIH) Studies Business (2020-2025)
11.20.5 bioaccess Recent Development
11.21 Pharmaron
11.21.1 Pharmaron Company Details
11.21.2 Pharmaron Business Overview
11.21.3 Pharmaron First in Human (FIH) Studies Introduction
11.21.4 Pharmaron Revenue in First in Human (FIH) Studies Business (2020-2025)
11.21.5 Pharmaron Recent Development
11.22 WuXi Clinical (WuXi AppTec)
11.22.1 WuXi Clinical (WuXi AppTec) Company Details
11.22.2 WuXi Clinical (WuXi AppTec) Business Overview
11.22.3 WuXi Clinical (WuXi AppTec) First in Human (FIH) Studies Introduction
11.22.4 WuXi Clinical (WuXi AppTec) Revenue in First in Human (FIH) Studies Business (2020-2025)
11.22.5 WuXi Clinical (WuXi AppTec) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global First in Human (FIH) Studies Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Healthy Volunteer Studies
Table 3. Key Players of Patient Population Studies
Table 4. Global First in Human (FIH) Studies Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global First in Human (FIH) Studies Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global First in Human (FIH) Studies Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global First in Human (FIH) Studies Market Share by Region (2020-2025)
Table 8. Global First in Human (FIH) Studies Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global First in Human (FIH) Studies Market Share by Region (2026-2031)
Table 10. First in Human (FIH) Studies Market Trends
Table 11. First in Human (FIH) Studies Market Drivers
Table 12. First in Human (FIH) Studies Market Challenges
Table 13. First in Human (FIH) Studies Market Restraints
Table 14. Global First in Human (FIH) Studies Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global First in Human (FIH) Studies Market Share by Players (2020-2025)
Table 16. Global Top First in Human (FIH) Studies Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in First in Human (FIH) Studies as of 2024)
Table 17. Ranking of Global Top First in Human (FIH) Studies Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by First in Human (FIH) Studies Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of First in Human (FIH) Studies, Headquarters and Area Served
Table 20. Global Key Players of First in Human (FIH) Studies, Product and Application
Table 21. Global Key Players of First in Human (FIH) Studies, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global First in Human (FIH) Studies Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global First in Human (FIH) Studies Revenue Market Share by Type (2020-2025)
Table 25. Global First in Human (FIH) Studies Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global First in Human (FIH) Studies Revenue Market Share by Type (2026-2031)
Table 27. Global First in Human (FIH) Studies Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global First in Human (FIH) Studies Revenue Market Share by Application (2020-2025)
Table 29. Global First in Human (FIH) Studies Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global First in Human (FIH) Studies Revenue Market Share by Application (2026-2031)
Table 31. North America First in Human (FIH) Studies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America First in Human (FIH) Studies Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America First in Human (FIH) Studies Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe First in Human (FIH) Studies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe First in Human (FIH) Studies Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe First in Human (FIH) Studies Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific First in Human (FIH) Studies Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific First in Human (FIH) Studies Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific First in Human (FIH) Studies Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America First in Human (FIH) Studies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America First in Human (FIH) Studies Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America First in Human (FIH) Studies Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa First in Human (FIH) Studies Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa First in Human (FIH) Studies Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa First in Human (FIH) Studies Market Size by Country (2026-2031) & (US$ Million)
Table 46. Precision for Medicine Company Details
Table 47. Precision for Medicine Business Overview
Table 48. Precision for Medicine First in Human (FIH) Studies Product
Table 49. Precision for Medicine Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 50. Precision for Medicine Recent Development
Table 51. Altasciences Company Details
Table 52. Altasciences Business Overview
Table 53. Altasciences First in Human (FIH) Studies Product
Table 54. Altasciences Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 55. Altasciences Recent Development
Table 56. hVIVO Company Details
Table 57. hVIVO Business Overview
Table 58. hVIVO First in Human (FIH) Studies Product
Table 59. hVIVO Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 60. hVIVO Recent Development
Table 61. QPS Holdings Company Details
Table 62. QPS Holdings Business Overview
Table 63. QPS Holdings First in Human (FIH) Studies Product
Table 64. QPS Holdings Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 65. QPS Holdings Recent Development
Table 66. Worldwide Clinical Trials Company Details
Table 67. Worldwide Clinical Trials Business Overview
Table 68. Worldwide Clinical Trials First in Human (FIH) Studies Product
Table 69. Worldwide Clinical Trials Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 70. Worldwide Clinical Trials Recent Development
Table 71. Veeda Lifesciences Company Details
Table 72. Veeda Lifesciences Business Overview
Table 73. Veeda Lifesciences First in Human (FIH) Studies Product
Table 74. Veeda Lifesciences Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 75. Veeda Lifesciences Recent Development
Table 76. CMAX Company Details
Table 77. CMAX Business Overview
Table 78. CMAX First in Human (FIH) Studies Product
Table 79. CMAX Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 80. CMAX Recent Development
Table 81. Hammersmith Medicines Research Company Details
Table 82. Hammersmith Medicines Research Business Overview
Table 83. Hammersmith Medicines Research First in Human (FIH) Studies Product
Table 84. Hammersmith Medicines Research Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 85. Hammersmith Medicines Research Recent Development
Table 86. Allucent Company Details
Table 87. Allucent Business Overview
Table 88. Allucent First in Human (FIH) Studies Product
Table 89. Allucent Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 90. Allucent Recent Development
Table 91. Aixial Group Company Details
Table 92. Aixial Group Business Overview
Table 93. Aixial Group First in Human (FIH) Studies Product
Table 94. Aixial Group Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 95. Aixial Group Recent Development
Table 96. Icon Group Company Details
Table 97. Icon Group Business Overview
Table 98. Icon Group First in Human (FIH) Studies Product
Table 99. Icon Group Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 100. Icon Group Recent Development
Table 101. BioPharma Services Company Details
Table 102. BioPharma Services Business Overview
Table 103. BioPharma Services First in Human (FIH) Studies Product
Table 104. BioPharma Services Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 105. BioPharma Services Recent Development
Table 106. Simbec-Orion Company Details
Table 107. Simbec-Orion Business Overview
Table 108. Simbec-Orion First in Human (FIH) Studies Product
Table 109. Simbec-Orion Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 110. Simbec-Orion Recent Development
Table 111. The Micron Group Company Details
Table 112. The Micron Group Business Overview
Table 113. The Micron Group First in Human (FIH) Studies Product
Table 114. The Micron Group Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 115. The Micron Group Recent Development
Table 116. BDD Company Details
Table 117. BDD Business Overview
Table 118. BDD First in Human (FIH) Studies Product
Table 119. BDD Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 120. BDD Recent Development
Table 121. TRACER Company Details
Table 122. TRACER Business Overview
Table 123. TRACER First in Human (FIH) Studies Product
Table 124. TRACER Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 125. TRACER Recent Development
Table 126. Sofpromed Company Details
Table 127. Sofpromed Business Overview
Table 128. Sofpromed First in Human (FIH) Studies Product
Table 129. Sofpromed Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 130. Sofpromed Recent Development
Table 131. Datapharm Australia Company Details
Table 132. Datapharm Australia Business Overview
Table 133. Datapharm Australia First in Human (FIH) Studies Product
Table 134. Datapharm Australia Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 135. Datapharm Australia Recent Development
Table 136. 3S Pharma Company Details
Table 137. 3S Pharma Business Overview
Table 138. 3S Pharma First in Human (FIH) Studies Product
Table 139. 3S Pharma Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 140. 3S Pharma Recent Development
Table 141. bioaccess Company Details
Table 142. bioaccess Business Overview
Table 143. bioaccess First in Human (FIH) Studies Product
Table 144. bioaccess Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 145. bioaccess Recent Development
Table 146. Pharmaron Company Details
Table 147. Pharmaron Business Overview
Table 148. Pharmaron First in Human (FIH) Studies Product
Table 149. Pharmaron Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 150. Pharmaron Recent Development
Table 151. WuXi Clinical (WuXi AppTec) Company Details
Table 152. WuXi Clinical (WuXi AppTec) Business Overview
Table 153. WuXi Clinical (WuXi AppTec) First in Human (FIH) Studies Product
Table 154. WuXi Clinical (WuXi AppTec) Revenue in First in Human (FIH) Studies Business (2020-2025) & (US$ Million)
Table 155. WuXi Clinical (WuXi AppTec) Recent Development
Table 156. Research Programs/Design for This Report
Table 157. Key Data Information from Secondary Sources
Table 158. Key Data Information from Primary Sources
Table 159. Authors List of This Report
List of Figures
Figure 1. First in Human (FIH) Studies Picture
Figure 2. Global First in Human (FIH) Studies Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global First in Human (FIH) Studies Market Share by Type: 2024 VS 2031
Figure 4. Healthy Volunteer Studies Features
Figure 5. Patient Population Studies Features
Figure 6. Global First in Human (FIH) Studies Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global First in Human (FIH) Studies Market Share by Application: 2024 VS 2031
Figure 8. Pharmaceutical Case Studies
Figure 9. Vaccine Case Studies
Figure 10. Others Case Studies
Figure 11. First in Human (FIH) Studies Report Years Considered
Figure 12. Global First in Human (FIH) Studies Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global First in Human (FIH) Studies Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global First in Human (FIH) Studies Market Share by Region: 2024 VS 2031
Figure 15. Global First in Human (FIH) Studies Market Share by Players in 2024
Figure 16. Global First in Human (FIH) Studies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 17. The Top 10 and 5 Players Market Share by First in Human (FIH) Studies Revenue in 2024
Figure 18. North America First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America First in Human (FIH) Studies Market Share by Country (2020-2031)
Figure 20. United States First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe First in Human (FIH) Studies Market Share by Country (2020-2031)
Figure 24. Germany First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Ireland First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific First in Human (FIH) Studies Market Share by Region (2020-2031)
Figure 32. China First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia & New Zealand First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America First in Human (FIH) Studies Market Share by Country (2020-2031)
Figure 40. Mexico First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa First in Human (FIH) Studies Market Share by Country (2020-2031)
Figure 44. Israel First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE First in Human (FIH) Studies Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Precision for Medicine Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 48. Altasciences Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 49. hVIVO Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 50. QPS Holdings Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 51. Worldwide Clinical Trials Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 52. Veeda Lifesciences Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 53. CMAX Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 54. Hammersmith Medicines Research Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 55. Allucent Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 56. Aixial Group Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 57. Icon Group Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 58. BioPharma Services Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 59. Simbec-Orion Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 60. The Micron Group Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 61. BDD Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 62. TRACER Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 63. Sofpromed Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 64. Datapharm Australia Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 65. 3S Pharma Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 66. bioaccess Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 67. Pharmaron Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 68. WuXi Clinical (WuXi AppTec) Revenue Growth Rate in First in Human (FIH) Studies Business (2020-2025)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
